Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1399: Passenger deletion vulnerability in glioblastoma

View through CrossRef
Abstract Glioblastoma multiforme (GBM) is the most common, aggressive and lethal primary brain tumor in humans. Despite aggressive therapy the median survival of GBM patients is approximately 15 months. Monoallelic loss of PTEN occurs in ~70% of GBM. Through experimental validation studies in patient-derived primary GBM cell lines, we discovered that the lipogenic gene SCD undergoes unintended co-deletion as a passenger to PTEN, resulting in hemizygous loss of SCD in a subset of GBM. Additional in silico, genetic and biochemical analysis lead to the identification of two distinct PTEN-deleted subgroups: one with hemizygous co-deletion of PTEN and SCD (hereafter SCD-expressing), and another with very little or no PTEN/SCD expression due to PTEN mutation/homozygous loss and epigenetic suppression of the remaining SCD allele (hereafter SCD-non-expressing). SCD is an integral membrane protein of the endoplasmic reticulum (ER), involved in mediating the rate-limiting step of unsaturated fatty acid biosynthesis. SCD catalyzes the desaturation of the saturated fatty acids stearic (C18:0) and palmitic acids (C16:0) to the monounsaturated fatty acids oleic (C18:1) and palmitoleic acids (C16:1), respectively. We showed that the SCD-expressing lines are highly sensitive to SCD inhibition in the absence of dietary oleate and that the SCD-non-expressing lines are resistant to SCD inhibition. In vivo, we showed that mice treated with the SCD inhibitor survive longer than mice treated with vehicle. We also showed that SCD-expressing GBM lines acquire inhibitor resistance upon long-term exposure to the inhibitor in vitro. To understand the mechanism of resistance, we performed Reverse Phase Protein Array (RRPA) and RNA-Seq. Results illustrated the up-regulation of SCD among other genes. To identify the gene/s that provide SCD inhibitor resistance, we are currently performing a targeted shRNA screen of the highly expressed genes that we determined through RPPA and RNA-Seq. Citation Format: Nicole Oatman, Kakajan Komurov, Priyanka Arora, Pankaj Desai, Nupur Dasgupta, Kwangmin Choi, Biplab Dasgupta. Passenger deletion vulnerability in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1399.
Title: Abstract 1399: Passenger deletion vulnerability in glioblastoma
Description:
Abstract Glioblastoma multiforme (GBM) is the most common, aggressive and lethal primary brain tumor in humans.
Despite aggressive therapy the median survival of GBM patients is approximately 15 months.
Monoallelic loss of PTEN occurs in ~70% of GBM.
Through experimental validation studies in patient-derived primary GBM cell lines, we discovered that the lipogenic gene SCD undergoes unintended co-deletion as a passenger to PTEN, resulting in hemizygous loss of SCD in a subset of GBM.
Additional in silico, genetic and biochemical analysis lead to the identification of two distinct PTEN-deleted subgroups: one with hemizygous co-deletion of PTEN and SCD (hereafter SCD-expressing), and another with very little or no PTEN/SCD expression due to PTEN mutation/homozygous loss and epigenetic suppression of the remaining SCD allele (hereafter SCD-non-expressing).
SCD is an integral membrane protein of the endoplasmic reticulum (ER), involved in mediating the rate-limiting step of unsaturated fatty acid biosynthesis.
SCD catalyzes the desaturation of the saturated fatty acids stearic (C18:0) and palmitic acids (C16:0) to the monounsaturated fatty acids oleic (C18:1) and palmitoleic acids (C16:1), respectively.
We showed that the SCD-expressing lines are highly sensitive to SCD inhibition in the absence of dietary oleate and that the SCD-non-expressing lines are resistant to SCD inhibition.
In vivo, we showed that mice treated with the SCD inhibitor survive longer than mice treated with vehicle.
We also showed that SCD-expressing GBM lines acquire inhibitor resistance upon long-term exposure to the inhibitor in vitro.
To understand the mechanism of resistance, we performed Reverse Phase Protein Array (RRPA) and RNA-Seq.
Results illustrated the up-regulation of SCD among other genes.
To identify the gene/s that provide SCD inhibitor resistance, we are currently performing a targeted shRNA screen of the highly expressed genes that we determined through RPPA and RNA-Seq.
Citation Format: Nicole Oatman, Kakajan Komurov, Priyanka Arora, Pankaj Desai, Nupur Dasgupta, Kwangmin Choi, Biplab Dasgupta.
Passenger deletion vulnerability in glioblastoma [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1399.

Related Results

Investigating the role of the apelinergic system in glioblastoma
Investigating the role of the apelinergic system in glioblastoma
<p>Elucidating the molecular signalling circuitry that underpins the pathogenesis of cancers is critical to understanding and developing effective treatment paradigms for can...
Understanding glioblastoma : cell identity in tissue space
Understanding glioblastoma : cell identity in tissue space
<p dir="ltr"><b>Abstract</b></p><p dir="ltr">Glioblastoma is the most prevalent form of brain cancer among adults. Inherently malignant and aggressive...
Understanding glioblastoma : cell identity in tissue space
Understanding glioblastoma : cell identity in tissue space
<p dir="ltr"><b>Abstract</b></p><p dir="ltr">Glioblastoma is the most prevalent form of brain cancer among adults. Inherently malignant and aggressive...
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
BCAT1 regulates glioblastoma cell plasticity and contributes to immunosuppression
Abstract Glioblastoma is the most common malignant brain tumor in adults. Cellular plasticity and the poorly differentiated features result in a ...
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma ...
The prognostic significance of XL DLEU/LAMP (13q14 deletion) in CCL patients: a cross section study
The prognostic significance of XL DLEU/LAMP (13q14 deletion) in CCL patients: a cross section study
Background: Many cytogenetic abnormalities were detected in CLL, one of them. Deletion of 13q14 region which is found in more than 50% of CLL patient. 13q deletion is the most comm...
Next steps in capturing vulnerability dynamics: Introducing a connectivity-based model on systemic vulnerability to multi-hazards
Next steps in capturing vulnerability dynamics: Introducing a connectivity-based model on systemic vulnerability to multi-hazards
Vulnerability has been acknowledged as a dynamic concept since the Pressure and Release model of Blaikie et al. (1994), as well as by other well-known models that integrate this ri...
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
P10.36.B ROLE OF AMPK IN GLIOBLASTOMA BIOENERGETICS
Abstract BACKGROUND Glioblastoma is the most prevalent and aggressive primary brain tumor. AMP-activated kinase (AMPK), the main...

Back to Top